Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06562998
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-08-18
Brief Title:
Pentoxifylline Role Against Chemotherapy-induced Neuropathy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Pentoxifylline Prophylactic Role Against Paclitaxel Chemotherapy-induced Neuropathy
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chemotherapy-induced peripheral neuropathy CIPN is a common and debilitating side effect of neurotoxic cancer treatment Estimated to occur in up to 80 of paclitaxel-treated patients with breast cancer neuropathy symptoms can interfere with function increasing the risk of falls and reducing quality of life To date there are no approved medications for the prevention andor treatment of CIPN The objective of the present study is to investigate the beneficial effects of pentoxifylline PTX against CIPN in breast cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None